Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer
Fallopian Tube Carcinoma, Infectious Disorder, Neutropenia
About this trial
This is an interventional treatment trial for Fallopian Tube Carcinoma
Eligibility Criteria
Inclusion Criteria: Diagnosis of 1 of the following: Primary peritoneal carcinoma Fallopian tube carcinoma Ovarian epithelial carcinoma Carcinosarcoma Stage III or IV disease Previously untreated disease, except for mandatory prior surgery No ovarian epithelial carcinoma of low malignant potential (i.e., borderline carcinomas) GOG performance status 0-2 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9.0 g/dL Creatinine ≤ 1.5 times upper limit of normal (ULN) Bilirubin ≤ 1.5 times ULN SGOT ≤ 2.5 times ULN Alkaline phosphatase ≤ 2.5 times ULN No peripheral neuropathy (sensory or motor) ≥ grade 2 Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No other invasive malignancies within the past 5 years except nonmelanoma skin cancer No septicemia, severe infection, or acute hepatitis No prior radiotherapy or chemotherapy No prior cancer treatment that would contraindicate study treatment
Sites / Locations
- University of California Medical Center At Irvine-Orange Campus
- University of Iowa Hospitals and Clinics
- Cooper Hospital University Medical Center
- New York University Langone Medical Center
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
- Riverside Methodist Hospital
- Lake University Ireland Cancer Center
- Cancer Care Associates-Midtown
- Women and Infants Hospital
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
- University of Washington Medical Center
Arms of the Study
Arm 1
Experimental
Treatment (carboplatin, paclitaxel, pegfilgrastim)
Patients receive carboplatin IV and paclitaxel IV over 3 hours on day 1. Patients also receive pegfilgrastim subcutaneously on day 2.